HLB Group to Host '2026 HLB Forum'... "Specifying Future Growth Direction"

HLB Group will host the '2026 HLB Forum' on May 12 and 13, focusing on in-depth discussions regarding the commercialization strategy for its global pipeline and the development direction of next-generation new drugs.

According to HLB Group on May 7, this forum will be held at the Sofitel Ambassador Seoul under the theme, “DNA of Success, Continuity of Innovation; Unstoppable Challenge.”

Bio affiliates within the group, together with pharmaceutical, biotech, and investment experts from Korea and abroad, will gather in one place to share global industry trends and review the progress and future direction of the group’s core pipelines.

The latest trends in the global biotechnology industry will be shared, along with updates on HLB Group’s new modality development. In-depth discussions will also be held regarding the development direction and commercialization plans for the next-generation oncology pipeline, following new drugs for liver and biliary tract cancers that are currently at the approval stage.

In particular, the progress and follow-up plans for each affiliate’s pipeline will be shared, and through discussions with domestic and international participants, concrete measures are expected to be proposed to further enhance development direction and execution capabilities.

There will also be presentations and discussions on a variety of topics, focusing on major issues in the pharmaceutical and biotech industries, including regulatory environments, development directions by disease, AI-based new drug development, investment trends, and case studies of entering the U.S. market.

Through this forum, HLB Group aims to consolidate its internal drug development capabilities and global network, strengthen cooperation among affiliates, and further enhance the commercialization potential of its technology and pipelines.

An HLB Group representative stated, “This forum is an opportunity to specify the group’s future growth direction, based on our accumulated new drug development experience and global expert network,” adding, “We will continuously advance our R&D and commercialization capabilities so that each affiliate’s pipeline can lead to tangible results in the global market.”

This content was produced with the assistance of AI translation services.